We subsequently confirmed that Ramatroban, an antagonist of PGD2 and TXA2 receptors, could successfully alleviate the progression of silicosis in a mouse model, indicating its potential clinical application for treating silicosis. This evidence concerns the gene HPGDS and silicosis.